{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:44:17Z","timestamp":1790682257241,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jaip.2022.03.034","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T02:47:40Z","timestamp":1650595660000},"page":"2125-2134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review"],"prefix":"10.1016","volume":"10","author":[{"given":"Gema","family":"Requena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Akuthota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kovalszki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Steinfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namhee","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa K.","family":"Van Dyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2022.03.034_bib1","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12016-015-8506-7","article-title":"Hypereosinophilic syndrome","volume":"50","author":"Curtis","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2022.03.034_bib2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.iac.2007.07.004","article-title":"Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders","volume":"27","author":"Ackerman","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2022.03.034_bib3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.iac.2015.04.002","article-title":"Spectrum of eosinophilic end-organ manifestations","volume":"35","author":"Akuthota","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2022.03.034_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.03.034_bib5","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood-2014-11-551614","article-title":"How I treat hypereosinophilic syndromes","volume":"126","author":"Klion","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.03.034_bib6","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/ajh.25617","article-title":"World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management","volume":"94","author":"Shomali","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2022.03.034_bib7","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.03.034_bib8","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fmed.2017.00216","article-title":"(A critical appraisal of) classification of hypereosinophilic disorders","volume":"4","author":"Kahn","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaip.2022.03.034_bib9","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaip.2017.06.006","article-title":"Hypereosinophilic syndrome subtype predicts responsiveness to glucocorticoids","volume":"6","author":"Khoury","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.03.034_bib10","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/all.12843","article-title":"Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome","volume":"71","author":"Khoury","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.03.034_bib11","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ajh.23193","article-title":"Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation","volume":"87","author":"Helbig","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2022.03.034_bib12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/hon.919","article-title":"Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study","volume":"28","author":"Helbig","year":"2010","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.jaip.2022.03.034_bib13","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/modpathol.2016.75","article-title":"Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified","volume":"29","author":"Wang","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jaip.2022.03.034_bib14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s12185-012-1141-7","article-title":"Response to imatinib mesylate in patients with hypereosinophilic syndrome","volume":"96","author":"Arefi","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jaip.2022.03.034_bib15","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3109\/10428194.2012.731602","article-title":"Diversity of clinical manifestations and response to corticosteroids for idiopathic hypereosinophilic syndrome: retrospective study in 33 patients","volume":"54","author":"Helbig","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaip.2022.03.034_bib16","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/00029330-200805020-00001","article-title":"FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib","volume":"121","author":"Wang","year":"2008","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.jaip.2022.03.034_bib17","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2007.05.024","article-title":"KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1\/PDGFRA-associated chronic eosinophilic leukemia are distinct entities","volume":"120","author":"Maric","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.03.034_bib18","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1038\/leu.2012.162","article-title":"Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome","volume":"26","author":"Pardanani","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2022.03.034_bib19","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MD.0b013e3182a71eba","article-title":"The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia: new insights based on a survey of 44 cases","volume":"92","author":"Legrand","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaip.2022.03.034_bib20","first-page":"255","article-title":"Exquisite response to imatinib mesylate in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome: a 12-year experience of the Polish Hypereosinophilic Syndrome Study Group","volume":"130","author":"Helbig","year":"2020","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.jaip.2022.03.034_bib21","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.leu.2403313","article-title":"Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias","volume":"18","author":"Vandenberghe","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2022.03.034_bib22","first-page":"596","article-title":"The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1\/PDGFRA but not genomic rearrangements of other tyrosine kinases","volume":"90","author":"La Starza","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.jaip.2022.03.034_bib23","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2141.2008.07294.x","article-title":"Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study","volume":"143","author":"Metzgeroth","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2022.03.034_bib24","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s12032-011-9831-1","article-title":"Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome","volume":"29","author":"Helbig","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.jaip.2022.03.034_bib25","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A\u00a0tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.03.034_bib26","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.leukres.2008.10.004","article-title":"Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status","volume":"33","author":"Jain","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaip.2022.03.034_bib27","doi-asserted-by":"crossref","first-page":"33229","DOI":"10.18632\/oncotarget.8906","article-title":"Long-term outcomes of imatinib in patients with FIP1L1\/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China","volume":"7","author":"Qu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaip.2022.03.034_bib28","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2018.052","article-title":"The spectrum of hypereosinophilia and associated clonal disorders\u2014a real-world data based on combined retrospective and prospective analysis from a tropical setting","volume":"10","author":"Sreedharanunni","year":"2018","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.jaip.2022.03.034_bib29","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jaip.2016.03.020","article-title":"Hypereosinophilia in children and adults: a retrospective comparison","volume":"4","author":"Williams","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.03.034_bib30","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1111\/bjh.16340","article-title":"Frequent false-negative FIP1L1-PDGFRA FISH analyses of bone marrow samples from clonal eosinophilia at diagnosis","volume":"188","author":"Olsson-Arvidsson","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2022.03.034_bib31","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13601-019-0277-4","article-title":"Eosinophilic disorders: evaluation of current classification and diagnostic criteria, proposal of a practical diagnostic algorithm","volume":"9","author":"Leru","year":"2019","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2022.03.034_bib32","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/asheducation-2011.1.257","article-title":"Eosinophilic myeloproliferative disorders","volume":"2011","author":"Klion","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jaip.2022.03.034_bib33","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/1744666X.2018.1425142","article-title":"Imatinib for the treatment of hypereosinophilic syndromes","volume":"14","author":"Helbig","year":"2018","journal-title":"Expert Rev Clin Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822003518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822003518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:33:25Z","timestamp":1761975205000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219822003518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2213219822003518"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2022.03.034","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2022.03.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}